Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

But more broadly, the technology could revolutionize many areas of ... The COVID-19 vaccines manufactured by Pfizer-BioNTech ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent off-target effects and treatment-resistant tumor microenvironments have ...

Biotechnology's rapid development of the future of medicine shows little sign of slowing down. We speak to the International ...